Markers of Inflammation and Lung Recovery in ECMO Patients for PPHN

Persistent Pulmonary Hypertension of the Newborn Clinical Trial

— Mi-ECMO  

Official title:

A Feasibility Study to Consider the Relationship Between Markers of Red Cell Damage, Inflammation and the Recovery Process of Newborns Requiring Extracorporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN): Mi-ECMO

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02940327
• Other study ID #: 0553
• Status: Completed
• Start date: February 19, 2016
• Est. completion date: July 10, 2017

Study information

• Verified date: May 2018
• Source: University of Leicester
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Respiratory failure in newborns is common and has high rates of death. Where conventional intensive care strategies have failed, newborn children are referred to treatment with Extra- Corporeal Membrane Oxygenation (ECMO). This involves connecting children via large bore cannulas placed in their heart and major blood vessels to an artificial lung that adds oxygen to their blood and removes waste gases (carbon dioxide). Although this treatment saves lives, it still has some limitations. In particular, severe complications like bleeding, or damage to the kidneys can occur. These complications can lead to death in some cases and long-term disability in others. Based on ongoing research in adults and children undergoing cardiac surgery the investigators have identified a new process that may underlie some of the complications observed in ECMO. The investigators have noted that when transfused blood is infused in an ECMO circuit, this results in the accelerated release of substances from the donor cells that cause organ damage; at least in adults. There are treatments that can reverse this process. Before the investigators explore whether these treatments should be used in newborn children on ECMO, the investigators must first demonstrate that they can measure the complex inflammatory processes that occur in these critically ill children. The investigators therefore propose to conduct a feasibility study to identify the practical issues and challenges that would need to be overcome in order to perform a successful trial in this high-risk population.

Description:

The primary hypothesis is that damage to red blood cells by the exposure to the ECMO circuit will result in inflammatory responses that mitigate against successful weaning from Extra-Corporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN).

The secondary hypothesis are:

1. Damage to red cells will result in platelet, leukocyte and endothelial activation.

2. Markers of platelet, endothelial and leukocyte activation are indicators of lung inflammation and injury severity and hence lung recovery.

3. Markers of platelet, endothelial and leukocyte activation are indicators of kidney injury severity and hence acute kidney injury.

4. The level of oxidative stress will correlate with type shifts in pulmonary macrophages, tissue iron deposition and organ injury.

5. Ability to raise anti-oxidative response, measured by Heme Oxigenase-1 (HMOX 1) expression, will correlate with shorter intubation times and less severe kidney and lung injury.

6. Granulocyte and platelets activation are secondary to rising redox potential and the levels of activation will correlate with longer intubation times and more severe organ injury.

7. Markers of anti-oxidative response, platelet, endothelial and leukocyte activation, as well as oxidative stress levels have diagnostic and prognostic utility for the prediction of key clinical events including delayed time to recovery, acute kidney injury in paediatric patients undergoing Extra-Corporeal Membrane Oxygenation (ECMO) for Persistent Pulmonary Hypertension of the Newborn (PPHN).

This is a pilot feasibility study that will establish the following:

1. Recruitment rates and patient flows for 24 patients specified as the target population for the feasibility study

2. Withdrawal rate, and completeness of follow-up and data collection in a paediatric population at high risk for death and major morbidity

3. The proportions (categorical data) and variance (continuous data) for the primary and secondary outcomes of interest. These will be used to model the sample sizes and outcomes that may be used in a definitive study

4. Perceptions of family members whose children participate in the study as to the appropriateness of the screening and consent process

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: July 10, 2017
• Est. primary completion date: July 10, 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 30 Days

Eligibility

Inclusion Criteria:

1. Patients with a diagnosis of PPHN

2. Patients that require ECMO support as determined by the ECMO team

3. Patients aged less than 30 days

4. Emergency consent obtained within 12 hours from cannulation, and ultimately full consent

Exclusion Criteria:

1. PPHN is caused by a congenital heart pathology

2. ECMO is required for a congenital heart disease

3. Lack of consent

Related Conditions & MeSH terms

• Hypertension
• Hypertension, Pulmonary
• Inflammation
• Persistent Fetal Circulation Syndrome
• Persistent Pulmonary Hypertension of the Newborn

Locations

Country	Name	City	State
United Kingdom	University Hospitals of Leicester NHS Trust	Leicester

Sponsors (4)

Lead Sponsor	Collaborator
University of Leicester	British Heart Foundation, Heart Link Children's Charity, University Hospitals, Leicester

Country where clinical trial is conducted

United Kingdom, 

References & Publications (57)

Akcan-Arikan A, Zappitelli M, Loftis LL, Washburn KK, Jefferson LS, Goldstein SL. Modified RIFLE criteria in critically ill children with acute kidney injury. Kidney Int. 2007 May;71(10):1028-35. Epub 2007 Mar 28. — View Citation

Bahrami KR, Van Meurs KP. ECMO for neonatal respiratory failure. Semin Perinatol. 2005 Feb;29(1):15-23. Review. — View Citation

Bendapudi P, Rao GG, Greenough A. Diagnosis and management of persistent pulmonary hypertension of the newborn. Paediatr Respir Rev. 2015 Jun;16(3):157-61. doi: 10.1016/j.prrv.2015.02.001. Epub 2015 Feb 10. Review. — View Citation

Bhutani VK. Developing a systems approach to prevent meconium aspiration syndrome: lessons learned from multinational studies. J Perinatol. 2008 Dec;28 Suppl 3:S30-5. doi: 10.1038/jp.2008.159. — View Citation

Biró E, Sturk-Maquelin KN, Vogel GM, Meuleman DG, Smit MJ, Hack CE, Sturk A, Nieuwland R. Human cell-derived microparticles promote thrombus formation in vivo in a tissue factor-dependent manner. J Thromb Haemost. 2003 Dec;1(12):2561-8. — View Citation

Brierley J, Larcher V. Emergency research in children: options for ethical recruitment. J Med Ethics. 2011 Jul;37(7):429-32. doi: 10.1136/jme.2010.040667. Epub 2011 Feb 23. — View Citation

Brittain EL, Janz DR, Austin ED, Bastarache JA, Wheeler LA, Ware LB, Hemnes AR. Elevation of plasma cell-free hemoglobin in pulmonary arterial hypertension. Chest. 2014 Dec;146(6):1478-1485. doi: 10.1378/chest.14-0809. — View Citation

Buehler PW, Baek JH, Lisk C, Connor I, Sullivan T, Kominsky D, Majka S, Stenmark KR, Nozik-Grayck E, Bonaventura J, Irwin DC. Free hemoglobin induction of pulmonary vascular disease: evidence for an inflammatory mechanism. Am J Physiol Lung Cell Mol Physiol. 2012 Aug 15;303(4):L312-26. doi: 10.1152/ajplung.00074.2012. Epub 2012 Jun 22. — View Citation

Butler J, Pathi VL, Paton RD, Logan RW, MacArthur KJ, Jamieson MP, Pollock JC. Acute-phase responses to cardiopulmonary bypass in children weighing less than 10 kilograms. Ann Thorac Surg. 1996 Aug;62(2):538-42. — View Citation

Chung J, Suzuki H, Tabuchi N, Sato K, Shibamiya A, Koyama T. Identification of tissue factor and platelet-derived particles on leukocytes during cardiopulmonary bypass by flow cytometry and immunoelectron microscopy. Thromb Haemost. 2007 Aug;98(2):368-74. — View Citation

Day JR, Taylor KM. The systemic inflammatory response syndrome and cardiopulmonary bypass. Int J Surg. 2005;3(2):129-40. Epub 2005 Aug 1. — View Citation

Farrow KN, Fliman P, Steinhorn RH. The diseases treated with ECMO: focus on PPHN. Semin Perinatol. 2005 Feb;29(1):8-14. Review. — View Citation

Fontaine D, Pradier O, Hacquebard M, Stefanidis C, Carpentier Y, de Canniere D, Fontaine J, Berkenboom G. Oxidative stress produced by circulating microparticles in on-pump but not in off-pump coronary surgery. Acta Cardiol. 2009 Dec;64(6):715-22. — View Citation

Fortenberry JD, Bhardwaj V, Niemer P, Cornish JD, Wright JA, Bland L. Neutrophil and cytokine activation with neonatal extracorporeal membrane oxygenation. J Pediatr. 1996 May;128(5 Pt 1):670-8. — View Citation

Fu L, Hu XX, Lin ZB, Chang FJ, Ou ZJ, Wang ZP, Ou JS. Circulating microparticles from patients with valvular heart disease and cardiac surgery inhibit endothelium-dependent vasodilation. J Thorac Cardiovasc Surg. 2015 Sep;150(3):666-72. doi: 10.1016/j.jtcvs.2015.05.069. Epub 2015 Jun 5. — View Citation

Golej J, Winter P, Schöffmann G, Kahlbacher H, Stoll E, Boigner H, Trittenwein G. Impact of extracorporeal membrane oxygenation modality on cytokine release during rescue from infant hypoxia. Shock. 2003 Aug;20(2):110-5. — View Citation

Graulich J, Walzog B, Marcinkowski M, Bauer K, Kössel H, Fuhrmann G, Bührer C, Gaehtgens P, Versmold HT. Leukocyte and endothelial activation in a laboratory model of extracorporeal membrane oxygenation (ECMO). Pediatr Res. 2000 Nov;48(5):679-84. — View Citation

Haase M, Bellomo R, Haase-Fielitz A. Novel biomarkers, oxidative stress, and the role of labile iron toxicity in cardiopulmonary bypass-associated acute kidney injury. J Am Coll Cardiol. 2010 May 11;55(19):2024-33. doi: 10.1016/j.jacc.2009.12.046. Review. — View Citation

Hanssen SJ, van de Poll MC, Houben AJ, Windsant IC, Snoeijs MG, Bekers O, Buurman WA, Jacobs MJ. Hemolysis compromises nitric oxide-dependent vasodilatory responses in patients undergoing major cardiovascular surgery. Thorac Cardiovasc Surg. 2012 Jun;60(4):255-61. doi: 10.1055/s-0031-1299571. Epub 2012 Mar 12. — View Citation

Howie SR. Blood sample volumes in child health research: review of safe limits. Bull World Health Organ. 2011 Jan 1;89(1):46-53. doi: 10.2471/BLT.10.080010. Epub 2010 Sep 10. Review. — View Citation

Irwin DC, Baek JH, Hassell K, Nuss R, Eigenberger P, Lisk C, Loomis Z, Maltzahn J, Stenmark KR, Nozik-Grayck E, Buehler PW. Hemoglobin-induced lung vascular oxidation, inflammation, and remodeling contribute to the progression of hypoxic pulmonary hypertension and is attenuated in rats with repeated-dose haptoglobin administration. Free Radic Biol Med. 2015 May;82:50-62. doi: 10.1016/j.freeradbiomed.2015.01.012. Epub 2015 Feb 2. — View Citation

Joffe S, Cook EF, Cleary PD, Clark JW, Weeks JC. Quality of informed consent: a new measure of understanding among research subjects. J Natl Cancer Inst. 2001 Jan 17;93(2):139-47. — View Citation

Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am. 2009 Jun;56(3):579-600, Table of Contents. doi: 10.1016/j.pcl.2009.04.004. Review. — View Citation

Kozik DJ, Tweddell JS. Characterizing the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg. 2006 Jun;81(6):S2347-54. Review. — View Citation

Larson MC, Hillery CA, Hogg N. Circulating membrane-derived microvesicles in redox biology. Free Radic Biol Med. 2014 Aug;73:214-28. doi: 10.1016/j.freeradbiomed.2014.04.017. Epub 2014 Apr 18. Review. — View Citation

Lazar DA, Cass DL, Olutoye OO, Welty SE, Fernandes CJ, Rycus PT, Lee TC. The use of ECMO for persistent pulmonary hypertension of the newborn: a decade of experience. J Surg Res. 2012 Oct;177(2):263-7. doi: 10.1016/j.jss.2012.07.058. Epub 2012 Aug 10. — View Citation

Lou S, MacLaren G, Best D, Delzoppo C, Butt W. Hemolysis in pediatric patients receiving centrifugal-pump extracorporeal membrane oxygenation: prevalence, risk factors, and outcomes. Crit Care Med. 2014 May;42(5):1213-20. doi: 10.1097/CCM.0000000000000128. — View Citation

Lovren F, Verma S. Evolving role of microparticles in the pathophysiology of endothelial dysfunction. Clin Chem. 2013 Aug;59(8):1166-74. doi: 10.1373/clinchem.2012.199711. Epub 2013 Mar 25. Review. — View Citation

Lubnow M, Philipp A, Foltan M, Bull Enger T, Lunz D, Bein T, Haneya A, Schmid C, Riegger G, Müller T, Lehle K. Technical complications during veno-venous extracorporeal membrane oxygenation and their relevance predicting a system-exchange--retrospective analysis of 265 cases. PLoS One. 2014 Dec 2;9(12):e112316. doi: 10.1371/journal.pone.0112316. eCollection 2014. — View Citation

Mamikonian LS, Mamo LB, Smith PB, Koo J, Lodge AJ, Turi JL. Cardiopulmonary bypass is associated with hemolysis and acute kidney injury in neonates, infants, and children*. Pediatr Crit Care Med. 2014 Mar;15(3):e111-9. doi: 10.1097/PCC.0000000000000047. — View Citation

Marc-Aurele KL, Steinman SL, Ransom KM, Finer NN, Dunn LB. Evaluation of the content and process of informed consent discussions for neonatal research. J Empir Res Hum Res Ethics. 2012 Jul;7(3):78-83. doi: 10.1525/jer.2012.7.3.78. — View Citation

Maslach-Hubbard A, Bratton SL. Extracorporeal membrane oxygenation for pediatric respiratory failure: History, development and current status. World J Crit Care Med. 2013 Nov 4;2(4):29-39. doi: 10.5492/wjccm.v2.i4.29. eCollection 2013 Nov 4. Review. — View Citation

McILwain RB, Timpa JG, Kurundkar AR, Holt DW, Kelly DR, Hartman YE, Neel ML, Karnatak RK, Schelonka RL, Anantharamaiah GM, Killingsworth CR, Maheshwari A. Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine. Lab Invest. 2010 Jan;90(1):128-39. doi: 10.1038/labinvest.2009.119. Epub 2009 Nov 9. — View Citation

McNally H, Bennett CC, Elbourne D, Field DJ; UK Collaborative ECMO Trial Group. United Kingdom collaborative randomized trial of neonatal extracorporeal membrane oxygenation: follow-up to age 7 years. Pediatrics. 2006 May;117(5):e845-54. Epub 2006 Apr 24. — View Citation

Meyer AD, Gelfond JA, Wiles AA, Freishtat RJ, Rais-Bahrami K. Platelet-derived microparticles generated by neonatal extracorporeal membrane oxygenation systems. ASAIO J. 2015 Jan-Feb;61(1):37-42. doi: 10.1097/MAT.0000000000000164. — View Citation

Mildner RJ, Taub N, Vyas JR, Killer HM, Firmin RK, Field DJ, Kotecha S. Cytokine imbalance in infants receiving extracorporeal membrane oxygenation for respiratory failure. Biol Neonate. 2005;88(4):321-7. Epub 2005 Aug 18. — View Citation

Modi N, Vohra J, Preston J, Elliott C, Van't Hoff W, Coad J, Gibson F, Partridge L, Brierley J, Larcher V, Greenough A; Working Party of the Royal College of Paediatrics and Child Health. Guidance on clinical research involving infants, children and young people: an update for researchers and research ethics committees. Arch Dis Child. 2014 Oct;99(10):887-91. doi: 10.1136/archdischild-2014-306444. Epub 2014 Jun 9. — View Citation

Mugford M, Elbourne D, Field D. Extracorporeal membrane oxygenation for severe respiratory failure in newborn infants. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001340. doi: 10.1002/14651858.CD001340.pub2. Review. — View Citation

Murphy GJ, Verheyden V, Wozniak M, Sullo N, Dott W, Bhudia S, Bittar N, Morris T, Ring A, Tebbatt A, Kumar T. Trial protocol for a randomised controlled trial of red cell washing for the attenuation of transfusion-associated organ injury in cardiac surgery: the REDWASH trial. Open Heart. 2016 Mar 7;3(1):e000344. doi: 10.1136/openhrt-2015-000344. eCollection 2016. — View Citation

Nascimbene A, Hernandez R, George JK, Parker A, Bergeron AL, Pradhan S, Vijayan KV, Civitello A, Simpson L, Nawrot M, Lee VV, Mallidi HR, Delgado RM, Dong JF, Frazier OH. Association between cell-derived microparticles and adverse events in patients with nonpulsatile left ventricular assist devices. J Heart Lung Transplant. 2014 May;33(5):470-7. doi: 10.1016/j.healun.2014.01.004. Epub 2014 Jan 19. — View Citation

Nieuwland R, Berckmans RJ, Rotteveel-Eijkman RC, Maquelin KN, Roozendaal KJ, Jansen PG, ten Have K, Eijsman L, Hack CE, Sturk A. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. Circulation. 1997 Nov 18;96(10):3534-41. — View Citation

Omar HR, Mirsaeidi M, Socias S, Sprenker C, Caldeira C, Camporesi EM, Mangar D. Plasma Free Hemoglobin Is an Independent Predictor of Mortality among Patients on Extracorporeal Membrane Oxygenation Support. PLoS One. 2015 Apr 22;10(4):e0124034. doi: 10.1371/journal.pone.0124034. eCollection 2015. — View Citation

Piccin A, Murphy WG, Smith OP. Circulating microparticles: pathophysiology and clinical implications. Blood Rev. 2007 May;21(3):157-71. Epub 2006 Nov 22. Review. — View Citation

Puthiyachirakkal M, Mhanna MJ. Pathophysiology, management, and outcome of persistent pulmonary hypertension of the newborn: a clinical review. Front Pediatr. 2013 Sep 2;1:23. doi: 10.3389/fped.2013.00023. Review. — View Citation

Rother RP, Bell L, Hillmen P, Gladwin MT. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. JAMA. 2005 Apr 6;293(13):1653-62. Review. — View Citation

Schaer DJ, Vinchi F, Ingoglia G, Tolosano E, Buehler PW. Haptoglobin, hemopexin, and related defense pathways-basic science, clinical perspectives, and drug development. Front Physiol. 2014 Oct 28;5:415. doi: 10.3389/fphys.2014.00415. eCollection 2014. Review. — View Citation

Schaible T, Hermle D, Loersch F, Demirakca S, Reinshagen K, Varnholt V. A 20-year experience on neonatal extracorporeal membrane oxygenation in a referral center. Intensive Care Med. 2010 Jul;36(7):1229-34. doi: 10.1007/s00134-010-1886-5. Epub 2010 Apr 28. — View Citation

Smith A, McCulloh RJ. Hemopexin and haptoglobin: allies against heme toxicity from hemoglobin not contenders. Front Physiol. 2015 Jun 30;6:187. doi: 10.3389/fphys.2015.00187. eCollection 2015. Review. — View Citation

Toomasian JM, Bartlett RH. Hemolysis and ECMO pumps in the 21st Century. Perfusion. 2011 Jan;26(1):5-6. doi: 10.1177/0267659110396015. — View Citation

UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. UK Collaborative ECMO Trail Group. Lancet. 1996 Jul 13;348(9020):75-82. — View Citation

Vermeulen Windsant IC, de Wit NC, Sertorio JT, van Bijnen AA, Ganushchak YM, Heijmans JH, Tanus-Santos JE, Jacobs MJ, Maessen JG, Buurman WA. Hemolysis during cardiac surgery is associated with increased intravascular nitric oxide consumption and perioperative kidney and intestinal tissue damage. Front Physiol. 2014 Sep 8;5:340. doi: 10.3389/fphys.2014.00340. eCollection 2014. — View Citation

Vermeulen Windsant IC, Hanssen SJ, Buurman WA, Jacobs MJ. Cardiovascular surgery and organ damage: time to reconsider the role of hemolysis. J Thorac Cardiovasc Surg. 2011 Jul;142(1):1-11. doi: 10.1016/j.jtcvs.2011.02.012. Epub 2011 May 13. Review. — View Citation

Warren OJ, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, Darzi AW, Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 1--mechanisms of pathogenesis. J Cardiothorac Vasc Anesth. 2009 Apr;23(2):223-31. doi: 10.1053/j.jvca.2008.08.007. Epub 2008 Oct 19. Review. — View Citation

Warren OJ, Watret AL, de Wit KL, Alexiou C, Vincent C, Darzi AW, Athanasiou T. The inflammatory response to cardiopulmonary bypass: part 2--anti-inflammatory therapeutic strategies. J Cardiothorac Vasc Anesth. 2009 Jun;23(3):384-93. doi: 10.1053/j.jvca.2008.09.007. Epub 2008 Dec 3. Review. — View Citation

Williams DC, Turi JL, Hornik CP, Bonadonna DK, Williford WL, Walczak RJ, Watt KM, Cheifetz IM. Circuit oxygenator contributes to extracorporeal membrane oxygenation-induced hemolysis. ASAIO J. 2015 Mar-Apr;61(2):190-5. doi: 10.1097/MAT.0000000000000173. — View Citation

Yong PJ, Koh CH, Shim WS. Endothelial microparticles: missing link in endothelial dysfunction? Eur J Prev Cardiol. 2013 Jun;20(3):496-512. doi: 10.1177/2047487312445001. Epub 2012 Apr 10. Review. — View Citation

Zwiers AJ, de Wildt SN, Hop WC, Dorresteijn EM, Gischler SJ, Tibboel D, Cransberg K. Acute kidney injury is a frequent complication in critically ill neonates receiving extracorporeal membrane oxygenation: a 14-year cohort study. Crit Care. 2013 Jul 24;17(4):R151. doi: 10.1186/cc12830. — View Citation

* Note: There are 57 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	CD16/41	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	12 hours after ECMO commencement
Primary	CD16/41	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	24 hours after ECMO commencement
Primary	CD16/41	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	48 hours after ECMO commencement
Primary	CD16/41	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	72 hours after ECMO commencement
Primary	CD16/41	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	24 hours after decannulation
Primary	CD14/41	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	12 hours after ECMO commencement
Primary	CD14/41	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	24 hours after ECMO commencement
Primary	CD14/41	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	48 hours after ECMO commencement
Primary	CD14/41	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	72 hours after ECMO commencement
Primary	CD14/41	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	24 hours after ECMO decannulation
Primary	CD64/163	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	12 hours after ECMO commencement
Primary	CD64/163	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	24 hours after ECMO commencement
Primary	CD64/163	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	48 hours after ECMO commencement
Primary	CD64/163	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	72 hours after ECMO commencement
Primary	CD64/163	Change of markers of platelet and leukocyte activation in arterial blood and analysed by flow cytometry.	24 hours after decannulation
Secondary	Change of Serum Haemoglobin Levels	Clinical and biochemical markers of organ failure	baseline
Secondary	Duration on ECMO	Clinical and biochemical markers of organ failure	> 7 days or did not survive to discharge
Secondary	Number of Participants With Acute Kidney Injury	Clinical and biochemical markers of organ failure	>7 days or did not survive to discharge
Secondary	Heart Injury as Determined by Serum Troponin Levels	Clinical and biochemical markers of organ failure	12 hours after ECMO commencement
Secondary	Allogenic Red Cell Transfusion Volume	Clinical and biochemical markers of organ failure	24 hours after ECMO is discontinued
Secondary	Number of Participants Requiring Non Red Cell Transfusion	Clinical and biochemical markers of organ failure	24 hours after ECMO is discontinued
Secondary	Heart Injury as Determined by Serum Troponin Levels	Clinical and biochemical markers of organ failure	24 hours after ECMO commencement
Secondary	Heart Injury as Determined by Serum Troponin Levels	Clinical and biochemical markers of organ failure	48 hours after ECMO commencement
Secondary	Heart Injury as Determined by Serum Troponin Levels	Clinical and biochemical markers of organ failure	72 hours after ECMO commencement
Secondary	Heart Injury as Determined by Serum Troponin Levels	Clinical and biochemical markers of organ failure	24 hours after decannulation
Secondary	Change of Serum Haemoglobin Levels	Clinical and biochemical markers of organ failure	12 hours after ECMO commencement
Secondary	Change of Serum Haemoglobin Levels	Clinical and biochemical markers of organ failure	24 hours after ECMO commencement
Secondary	Change of Serum Haemoglobin Levels	Clinical and biochemical markers of organ failure	48 hours after ECMO commencement
Secondary	Change of Serum Haemoglobin Levels	Clinical and biochemical markers of organ failure	72 hours after ECMO commencement
Secondary	Change of Serum Haemoglobin Levels	Clinical and biochemical markers of organ failure	24 hours after decannulation